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Resumen
Objetivo: El presente artículo resume el 
apoyo empírico actual para el Entrenamiento 
de la Adaptación de la Memoria y la Atención 
(MAAT), un programa de tratamiento cogniti-
vo-conductual que utiliza un enfoque de es-
trategia compensatoria para el manejo de los 
efectos cognitivos tardíos de la quimioterapia 
en los supervivientes del cáncer. Se presenta 
una descripción del MAAT, además de otros 
enfoques de tratamiento. Resultados: Es ne-
cesario ampliar los métodos actuales de eva-
luación de las mejorías del tratamiento en los 
supervivientes de cáncer con problemas cogni-
tivos que han completado programas como el 
MAAT. En este sentido, se propone una tabla 
de medidas de resultado informadas (PRO) por 
el paciente que puede ser más adecuada para 
la investigación de resultados futuros. Conclu-
siones: Identificar medidas de de resultado que 
evalúen con precisión los objetivos clínicos del 
MAAT y otros tratamientos conductuales es de 
vital importancia, ya que algunas variables (ej., 
calidad de vida, estrés de rol), no son detecta-
dos por pruebas neuropsicológicas de modo 
aislado. La tabla de PRO presentada en este 
artículo tiene el propósito de ayudar a los futu-
ros investigadores a identificar las medidas que 
pueden reflejar la mejoría en calidad de vida 
en respuesta a tratamientos como el MAAT.
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Abstract
Objective: This article summarizes current 
empirical support for Memory and Attention 
Adaptation Training (MAAT), a cognitive-behavioral 
treatment program that uses a compensatory 
strategy approach for management of late 
cognitive effects of chemotherapy among cancer 
survivors. A description of MAAT, in addition 
to other treatment approaches, is presented. 
Results: Current methods of assessing treatment 
gains among cancer survivors with cognitive 
problems who have completed programs such as 
MAAT need to be expanded. As such, a table of 
patient reported outcome (PRO) measures that 
may be better suited for future outcome research 
is proposed. Conclusions: Identifying outcome 
measures that accurately assess the clinical 
targets of MAAT and other behavioral treatments 
is of prime importance, as certain variables (e.g., 
quality of life, role strain) are not detected by 
neuropsychological testing in isolation. The PRO 
table presented in this article is intended to aid 
future researchers in identifying measures that 
can reflect quality of life improvement in response 
to treatments such as MAAT.
Keywords: Chemotherapy, cognitive 
dysfunction, cancer survivorship, cognitive-
behavioral therapy.
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INTRODUCTION
Cognitive impairment associated 
with chemotherapy and its impact on 
cancer survivor quality of life has gained 
increased interest among clinical research 
investigators over the last 2 decades(1-3). One 
of the most feared health problems among 
members of the general public is cognitive 
decline(4-5). With growing numbers of 
individuals living longer with a cancer 
diagnosis (estimated at 11.7 million 
and growing in the United States)(6-7), 
research on the neuropsychological 
impact of chemotherapy has gained in 
importance. The discussion to follow 
outlines development and research of a 
cognitive-behavioral treatment approach 
to help mitigate the health-related quality 
of life impact of chemotherapy-related 
cognitive dysfunction. First, a summary of 
the empirical literature to date regarding 
the impact of chemotherapy on cognitive 
function and quality of life will be provided, 
followed by an overview of Memory and 
Attention Adaptation Training (MAAT) and 
the research on this treatment approach. 
Last, we will summarize recommended 
steps in future research and other treatment 
approaches in this area.
NEUROPSYCHOLOGICAL IMPACT OF 
CHEMOTHERAPY 
Research on the neuropsychological 
impact of cancer treatment dates back to 
the early 1980s with studies suggesting 
patients treated with chemotherapy 
experience measurable cognitive deficits 
on standard neuropsychological tests(8). 
Historically, the largest body of research 
with the highest quality designs has been 
conducted in children(9-11) but interest grew 
with adult populations. Initially, smaller 
studies with cross-sectional designs 
compared groups of individuals who had 
the same cancer diagnosis but differed in 
treatment approach –that is, chemotherapy 
vs. nonchemotherapy recipients–. One 
example was an early study by Wieneke 
and Dienst(12) that evaluated 28 women 
with a standardized neuropsychological 
test battery an average of 6 months post-
treatment with CAF (cyclophosphamide, 
doxorubicin and 5-fluorouracil) and/or 
CMF (cyclophosphamide, methotrexate, 
and 5-fluorouracil). Seventy-five percent 
of patients scored greater than 2 standard 
deviations below published norms on one 
or more of neuropsychological measures, 
lending preliminary support to the notion 
that chemotherapy can negatively affect an 
individual’s later cognitive abilities.
In a larger study, Ahles et al.(13) 
compared long-term breast cancer and 
lymphoma survivors (> 5 years post-
treatment) who completed chemotherapy 
or local therapy (e.g., localized radiation 
therapy). Survivors were matched on 
age, education, IQ, menopausal status 
and were excluded if they had histories 
of neurologic, substance abuse or severe 
psychiatric illness. Multivariate analyses 
demonstrated between group differences in 
Verbal Memory (p<0.01) and Psychomotor 
Processing Speed (p<0.03). Using a 
definition of low neuropsychological 
performance similar to that used in other 
studies (lower 25th percentile), 39% of 
chemotherapy patients compared to 14% 
of local therapy patients scored within 
the low performance range (p<0.002). In 
short, Ahles et al. demonstrated cognitive 
effects of chemotherapy could be long-
Palabras claves: Quimioterapia, disfunción 
cognitiva, supervivencia al cáncer, terapia 
cognitivo-conductual. 
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term and not attributable to previous 
brain injury, age, education, gender, 
menopausal status or IQ. However, Ahles 
and colleagues did not report differences 
between types of chemotherapy received, 
and to date it is unclear which anti-
neoplastic agents are more likely to spawn 
cognitive impairments(14-17). In addition to 
the examples of cross-sectional studies 
cited above, longitudinal studies were 
undertaken. In two examples, researchers 
assessed breast cancer patients with 
standardized neuropsychological tests 
prior to chemotherapy and 6-months post-
treatment(18,19). Comparison groups either 
involved healthy controls or breast cancer 
patients on experimental therapies. In 
one of these studies, Shilling and et al.(19) 
identified 34% of chemotherapy recipients 
with cognitive impairment at 6 months 
post-treatment in comparison with 18.6 
% of control participants. These and other 
longitudinal studies appear consistent with 
previous cross-sectional designs suggesting 
that for a subset of survivors who receive 
adjuvant chemotherapy, there are 
detectable neuropsychological declines. In 
summary, the body of evidence supports 
the hypothesis that chemotherapy can lead 
to long-standing cognitive change for some 
survivors(20,21). Overall, three principal 
conclusions that can be drawn from this 
literature are:
1) A subset of individuals (ranging from 
about 20 to 40%) experience mild 
to moderate cognitive decline in 
comparison to matched controls(21);
2) Cognitive declines do not appear to 
be associated with age, education, 
neurologic history, psychiatric history, 
stress or menopausal status as the bulk 
of studies have controlled for these 
factors(17); and
3) Mild cognitive decline appears 
long term and in domains of verbal 
memory, working memory and visual 
motor processing speed(16,21). These 
declines are believed to be static and 
not progressive; that is, there is little 
evidence that cognitive decline after 
chemotherapy is progressive such as 
that seen in serious forms of dementia. 
QUALITY OF LIFE AND FUNCTIONAL 
IMPACT OF COGNITIVE DYSFUNCTION 
The research cited above is primarily 
concerned with identifying rates 
of neuropsychological impairment 
in chemotherapy recipients using 
standardized neuropsychological tests; it 
is less focused on quality of life impact 
cognitive problems can produce(21,22). By 
contrast, a recent online survey of 453 
cancer survivors evaluated functional 
and quality of life impact (www.
hurricanevoices.org/today/cognition). 
This survey was overseen by Ian 
Tannock MD, PhD, FRCPC and Janette 
Vardy PhD, MEd, FRACP, who are well 
known for their investigations in the 
area of chemotherapy-related cognitive 
dysfunction. Of survivors responding, 
62% noted cognitive problems affected 
role function in relationships at home 
and employment. Reports of home-related 
problems included being criticized or 
“supervised” by family members, avoiding 
social functions due to embarrassment 
with memory lapses (a common report in 
previous Memory and Attention Adaptation 
Training —MAAT— research) and change 
in family roles with children taking on 
more responsibility. Reports of work-
related problems included shifting to jobs 
with fewer responsibilities and lower pay, 
inability to “multi-task” and handle pre-
cancer work load, frustration exhibited 
by co-workers or supervisors and in some 
instances termination (another report in 
previous MAAT research). A controlled 
empirical study (cross-sectional design) 
reports similar quality of life effects (23). 
Breast cancer and lymphoma survivors 
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who had chemotherapy found diminished 
social role function and less home activity 
than non-chemotherapy counterparts(23). 
Finally, among surveyed survivors 
who report seeking help from their 
oncologists regarding the aforementioned 
problems, 55% reported their oncologist 
as understanding. However, only 10% 
reported they were offered assistance to 
deal with the problem(s). While this latter 
point appears negative, it is emphasized 
that the problem of chemotherapy-
associated cognitive change is complex 
and treatment strategies are only beginning 
to be developed and evaluated. Therefore, 
oncology providers have few readily 
available options to help survivors at 
present. MAAT was developed in response 
to this void in survivor treatment offerings.
 
MAAT: BACKGROUND AND RATIONALE
MAAT was developed as a brief 
intervention to minimize the impact of 
cognitive change on quality of life and role 
function among adult cancer survivors. To 
date, no treatment is conclusively efficacious 
for adults who experience chemotherapy-
related cognitive change. Historically, 
pediatric psychosocial oncology appeared 
more advanced in addressing cognitive 
problems among survivors. In particular, 
Butler and Copeland(24) developed a 
treatment program for children with 
central nervous system (CNS) disease 
and who have undergone a variety of 
cancer treatments that can adversely affect 
cognitive development and function (e.g., 
intracranial irradiation, surgery, systemic 
chemotherapies or intrathecal therapies). 
Results from their multi-site, waitlist 
randomized control trial (RCT) of the 
Cognitive Remediation Program (CRP)(25) 
suggest children improved on measures 
of academic achievement (as assessed 
by the Wide Range Achievement Test-3) 
and in parent ratings of inattention and 
hyperactivity (as assessed by Conner’s 
Parent Rating Scales). Furthermore, CRP 
children also tended to report use of more 
meta-cognitive strategies in academic tasks 
than wait-list controls. 
While these results are encouraging for 
children and adolescents, the CRP may 
not be suited to adult cancer survivors for 
several reasons. First, cognitive dysfunction 
observed in the Butler et al. sample may 
be more profound than the mild cognitive 
change commonly observed in adults 
after systemic chemotherapy with no CNS 
disease. Second, the CRP program can be 
lengthy with high time demand (up to 20 
2-hour sessions) to accommodate complex 
cognitive developmental factors seen in 
pediatric cases (e.g., neurophysiological 
damage in a developing brain co-mingled 
with social/emotional development). The 
CRP may thus be too disruptive and costly 
in terms of time and expense for adult 
survivors who are resuming functional 
roles after cancer treatment. 
THEORETICAL UNDERPINNINGS OF 
MAAT
In the cognitive rehabilitation literature, 
two broad approaches emerge: 1) A 
rehabilitation approach that emphasizes 
repetitive practice of cognitive tasks 
to promote neural circuitry repair or 
cortical reorganization(26,27); and 2) A 
“compensatory strategy” approach. There 
is evidence that repetitive practice can 
enhance brain plasticity(28,29) and directly 
affect underlying neurocircuitry involved 
in cognitive function. By contrast, the 
compensatory strategy approach places 
emphasis on the acquisition of adaptive 
behavioral and cognitive skills to optimize 
cognitive task performance-presumably 
using retained or unaffected brain regions 
after neurophysiological insult(30,31). 
This approach tends to directly address 
behavioral memory-related disability; that 
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is, improve performance on daily tasks 
for which memory is used(26) . Therefore, 
the primary outcomes of interest with 
a compensatory approach are not 
neuropsychological testing score gains per 
se, but rather measures that are sensitive to 
enhanced function and quality of life. 
There is ongoing debate about 
the effectiveness of repetitive practice 
versus compensatory/adaptive strategy 
approaches. Although such a discussion 
is beyond the scope of this article, 
in general, the repetitive practice 
rehabilitation approach appears to have 
overall moderate effects on memory 
function among individuals with more 
severe neuropsychological impairment 
secondary to stroke or other acquired 
brain injury(26). At the same time, there 
is evidence that compensatory strategy 
training may help individuals generalize 
(or “transfer”) cognitive compensatory 
skills to daily life across multiple settings 
to promote adaptation to cognitive 
problems. Traditional repetitive practice 
may only improve performance on unitary 
tasks(26,31-34). 
MAAT was designed by the primary 
author with the compensatory strategy 
approach in mind. A principal aim of 
MAAT is to improve self-management 
and coping with cognitive failures in 
daily life to enhance overall quality of 
life and function. MAAT is also consistent 
with a cognitive-behavioral therapy (CBT) 
model, where the over-arching goal is to 
enhance adaptive behavioral and cognitive 
responses to minimize the deleterious 
effects of symptoms on function. A 
parallel illustration of this approach is 
the cognitive-behavioral management 
of chronic pain(35). In that literature, 
studies indicate CBT generally does not 
produce substantive reductions in overall 
report of pain intensity in many cases. 
CBT does, however, produce significant 
gains in various domains of life among 
pain sufferers, including improvements 
in social, emotional, occupational and 
physical function, despite persistent 
chronic pain(25-37). Likewise, MAAT 
emphasizes quality of life gains through 
adaptive self-management skill acquisition 
despite persistence of some cognitive 
dysfunction(34,38-40).
On a final note of theoretical 
underpinnings, MAAT conceptualizes che-
mo the rapy-related cognitive dysfunction 
from a “diathesis-stress” framework. That 
is, under times of low demand such as 
smooth work or home routines, cognitive 
dysfunction may not cause undue life 
interference. If memory problems arise 
under times of low demand/stress, 
they are readily handled or are of little 
consequence. By contrast, under times 
of high performance demand, such as 
sales presentations, dispensing dangerous 
medications, or making parenting decisions, 
cognitive failures may cause greater 
interference and distress. MAAT is not 
concerned with the neurobiological causes 
of memory and attention failures. Indeed, 
as reviewed previously, the mechanisms 
by which cancer chemotherapies disturb 
functions of memory and attention remain 
unknown. Therefore, MAAT is based on 
social learning principles common to other 
cognitive-behavioral approaches. The goals 
of treatment are to modify maladaptive 
cognitions (beliefs, attitudes) and behaviors 
in order to bring about optimal adaptation 
to living with newly acquired cognitive 
effects of cancer treatment. Although 
neuropsychological test performance 
may improve as an effect of MAAT, 
it is contended here that changes in 
neuropsychological test scores may not be 
as clinically meaningful as improvements 
in measures of daily function or quality of 
life for individual cancer survivors(17,22). As 
it may not be fully possible to eliminate 
life experiences such as physical pain or 
anxiety, it is not possible to fully eliminate 
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daily cognitive failures of memory and 
attention as these are daily experiences in 
of healthy individuals(41,43).
MAAT COMPONENTS 
MAAT draws from the CBT and 
rehabilitation evidence base related to mild 
traumatic brain injury, cerebral damage due 
to stroke or other trauma recovery(26,27,32,43-47). 
There are four components to MAAT: 1) 
education (on chemotherapy and cancer-
treatment related cognitive problems, 
cognitive symptom re-attribution, and 
other influences on attention and memory 
such as stress); 2) self-awareness training 
(self-monitoring to identify “at risk” 
conditions where cognitive failures occur); 
3) self-regulation (emphasis on arousal self-
regulation, relaxation and stress coping 
skills) and 4) compensatory strategies(39,40). 
Each component is presented in serial 
fashion over the course of 8 weekly MAAT 
visits, ranging from 45 to 50 minutes in 
duration.
Education. The educational component 
of MAAT consists of reviewing the current 
understanding of how chemotherapies 
can influence memory function and how 
other cancer treatments, such as hormonal 
therapies, can affect cognitive function. 
Time is also devoted to reviewing basic 
memory and attention functions and 
illustrating how much of everyday memory 
failure is normal. The intent of the latter 
educational point is to help reduce 
misattribution of everyday memory failure 
to chemotherapy causes when it could 
be due to inattention, distraction, stress, 
emotional arousal, hunger, fatigue, etc. It 
is emphasized strongly to the survivor that 
this information is not intended to dismiss 
or minimize their cognitive complaints. 
Rather, the intent is to have the survivor 
recognize that while some daily cognitive 
failures may be due to cancer treatment, 
certainly not all are going to be. Some 
may be due to environmental factors (e.g., 
visual or auditory distractions) or internal 
states (excessive stress responding) that can 
be readily modified. This “re-attribution” 
element of MAAT is considered critical to 
starting a healthy cognitive self-appraisal 
process that can reduce distress about 
cognitive failures after cancer treatment. 
This sets the stage to enhance beliefs of 
self-efficacy in coping with the problems. 
Expectations about cognitive symptoms are 
associated with stronger perceptions of pre-
to-post brain injury symptom change(43) and 
can lead to reduced neuropsychological 
test performance in a “self-fulfilling” 
prophecy fashion(48). Therefore, by 
modifying survivors’ self-appraisal of 
cognitive symptoms experienced from 
uncontrollable to more controllable causal 
attributions, this will likely lead to less 
distress about memory failures when they 
occur. 
Self-awareness training. This component 
of MAAT refers to survivors using a brief 
self-monitoring form to record memory 
and attention failures. Obviously, given the 
common rates of daily memory failure in 
healthy individuals, survivors are not asked 
to record every memory failure but to 
gather a sample of those cognitive failures 
that produce distress and performance 
interference. Each “Memory and Attention 
Problem Record” evaluates the intensity of 
how much distress each failure causes, the 
nature of the cognitive failure (cognitive 
task demands), the environmental (e.g., 
ambient auditory or visual distractions), 
and internal (e.g., fatigue, emotional 
distress such as anxiety, hunger, etc.) 
antecedents. This information is reviewed 
with the clinician and helps identify the 
“at risk” situations where cognitive failures 
are more likely. Self-awareness also helps 
guide the selection of the most applicable 
cognitive compensatory strategies to either 
prevent cognitive failures or minimize their 
quality of life impact.
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Self-regulation. Self-regulation refers 
to applied relaxation training methods 
of progressive muscle relaxation (PMR) 
and cue-controlled or “quick” relaxation. 
The intent is to enhance survivors’ skills 
to regulate psychophysiological arousal 
that can interfere with cognitive processes 
such as attention, encoding and recall. An 
emphasis is placed on mindfulness or greater 
awareness of relaxing skeletal muscles and 
self-regulating breathing during everyday 
tasks to generalize the skill to daily life. 
In addition to relaxation, other self-
regulation methods that emphasize stress 
management include activity scheduling 
and pacing, or the scheduling of pleasant 
or achievement oriented tasks to optimize 
mood management that can positively 
influence cognitive performance(49). In the 
latest version of MAAT, methods of sleep 
quality improvement and managing fatigue 
with pacing and goal setting have been 
added to this component.
Compensatory Strategies. Compen sa-
tory strategies are defined as behavioral 
or cognitive skills and external devices 
(such as day-planners, electronic devices 
or visual or auditory prompts) that help 
prevent or mitigate adverse consequences 
of memory failures in daily life. Other 
compensatory strategies in MAAT includes 
verbal rehearsal methods such as repeating 
information to aid encoding or “holding” 
the information long enough to perform 
an action (such as dial a phone number 
or enter it into a computer data base). 
“Spaced rehearsal” is a form of verbal 
rehearsal where the interval of repeating 
information is gradually lengthened with 
each repetition— in a sense, a practical 
“exercise” for working memory and short-
term or delayed recall. Self-instructional 
training (SIT) is another method of “talking 
to one’s self” to aid focused attention during 
procedural task performance to reduce 
error in missing steps in the task(50,51). 
In addition to these internal strategies, 
there are host of external strategies(52) 
such as using a day planner to keep a 
simplified, organized schedule, either 
paper or electronic device, establishment 
of memory routines at work or home, or 
using external visual or auditory cues (cell 
phone alert) to cue specific behavior. In 
each MAAT visit, the clinician reviews the 
rationale of the compensatory strategy, 
rehearses the strategy with the survivor, 
and identifies where and when the strategy 
will be applied in daily activity.
EMPIRICAL SUPPORT FOR MAAT
In initial development, MAAT was 
characterized as a “guided self-help” CBT 
in which the survivor uses a workbook in 
conjunction with clinician interactions. 
The brief format was intended to optimize 
wide spread use and reduce survivor 
office visit burden, particularly in rural 
regions where people live long distances 
from comprehensive cancer centers(53). 
The initial edition of MAAT consisted of 
4 individual office visits once every 4 
weeks, with 3 phone contacts (1 between 
each visit) for support and to review daily 
homework. After two studies conducted on 
MAAT feasibility and preliminary efficacy, 
however, MAAT has been modified to 8 
weekly, 45-50 minute visits.
Pilot research points to support of 
MAAT feasibility and positive impact 
on quality of life gains. In a single-arm 
pilot study(38), 29 breast cancer survivors 
(average 8.2 years post-chemotherapy; SD 
= 4.4 years) completed MAAT. Principal 
outcome measures included self-reported 
cognitive function in daily life as assessed 
by The Multiple Ability Self-Report 
Questionnaire (MASQ)(54), The Quality 
of Life- Cancer Survivors scale (QOL-
CS(55)), satisfaction ratings and a brief 
neuropsychological test battery. Testing 
occurred at 4 time points: baseline, post-
treatment, 2-month and 6-month follow-
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up. Survivors were excluded if they had 
any history of neurological problems 
such as prior traumatic brain injury or 
central nervous system disease, substance 
addiction, or severe psychiatric illness. 
Results indicated a significant reduction 
in self-reported daily cognitive complaints 
(MASQ), improved quality of life and high 
satisfaction ratings. Neuropsychological 
test score improvements were observed 
in verbal memory and processing speed. 
Although positive, neuropsychological 
results were interpreted with caution as 
there was no control group to rule out 
effects of practice with repeat testing. 
Nonetheless, the pilot results did support 
primary aims of the proposed study, helped 
to identify modifications to the MAAT 
format (such as placing visits 2 weeks apart 
rather than one month apart) and thus set 
the stage for further MAAT evaluation.
In the second study of MAAT, a small 
RCT utilizing a waitlist control design was 
completed(40). The intent was to establish 
preliminary efficacy of MAAT and identify 
possible areas of treatment improvement. 
Forty women were enrolled and randomized 
to treatment (n = 19) or waitlist control (n 
= 21) conditions and assessed at baseline, 
post-treatment and 2 month follow-up time 
points. Participants were 18 months post-
chemotherapy and the exclusionary criteria 
were identical to the one-group pilot study 
of MAAT (e.g., no neurological, psychiatric 
or substance addiction history). Of 53 
individuals initially screened via telephone 
for participation, 40 were randomized to 
MAAT or waitlist control conditions. The 
mean age of the final sample was 50.3 
years (SD = 6.4). Five participants did not 
complete the three assessment points and 
linear interpolation methods were used 
to account for missing data in this small 
trial. A 2 (MAAT vs. Waitlist control) X 3 
(Baseline, post-treatment and follow-up) 
multivariate, repeated measures analysis 
of variance was employed for statistical 
analysis. Dependent measures included 
those used in the previous study: the 
MASQ total score, QOL-CS and a brief 
neuropsychological test battery. Within-
group effect sizes (Cohen’s d) were 
calculated to examine baseline to post-
treatment and follow-up effects to detect 
magnitude of MAAT treatment effects. 
Subtracting waitlist control group effect size 
from MAAT effect size was completed to 
estimate “true” MAAT effect by accounting 
for study demand characteristics such as 
expectations of being enrolled in a research 
study and/or practice effects with repeat 
administration of neuropsychological 
tests. This method has been used in 
meta-analyses of cognitive rehabilitation 
approaches by Rohling et al.(26)
Correlation analyses demonstrated 
education (in years) and IQ (estimated by 
demographic factors(56)) were covariates. 
Accounting for these 2 variables, MAAT 
participants made significant improvements 
over waitlist control participants on the 
QOL-CS Spiritual Wellbeing subscale and 
on CVLT-2 total score-or verbal memory. 
The outcome of the QOL-CS Spiritual 
Wellbeing subscale is likely due to the 
item content of the 7-item scale; the items 
reflect general positivism and hopefulness 
in cancer survivorship. MAAT is aimed at 
enhancing self-management of and coping 
with cognitive symptoms. Therefore, 
participants likely made improvements 
in coping that may be reflected in the 
QOL-CS Spiritual Wellbeing subscale 
changes. The CVLT-2 total score gains 
suggest MAAT compensatory strategies 
may be relatively more helpful for the 
verbal memory domain than in domains 
of visual motor processing speed, although 
MAAT participants made some statistically 
non-significant gains in the digit-symbol 
subtest. In addition, MAAT participants 
did not differ significantly on self-report of 
daily cognitive complaints (as assessed by 
MASQ total score) from controls. However, 
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the pre-to-post-treatment effect size for the 
MASQ total score was .43 after subtracting 
control group size of effect. In addition, 
effect sizes in the QOL-CS Spiritual 
Wellbeing and CVLT-2 total score results 
were -.49 and -.50, respectively (note that 
the negative sign does not change the 
magnitude of effect; this reflects the fact 
that MAAT participant scores improved 
on both measures where higher scores 
indicate improvement). The CVLT-2 total 
score effect size was -.63 at 2-month 
follow-up. In summary, while the waitlist 
RCT was small and likely underpowered, 
MAAT participants appeared to improve 
more than controls in one quality of life 
measure and verbal memory performance 
with moderate to stronger effects. Overall, 
research on MAAT thus far encourages 
further development and investigation 
of MAAT as a treatment option for adult 
cancer survivors with post-cancer treatment 
memory problems. 
CONTINUED MAAT DEVELOPMENT 
AND FUTURE DIRECTIONS 
Several concerns about MAAT remain 
and should be addressed in continued 
research. First, a major weakness is that no 
MAAT research to date has used an active 
treatment control condition. One RCT 
is underway using a supportive therapy 
control condition vs. MAAT with the both 
treatment conditions being delivered via 
videoconference rather than face to face 
clinical delivery. However, this is another 
somewhat small trial (N=48; 24 participants 
per condition). While such research is a 
step in the right direction, clearly, a larger 
RCT using an active attention-treatment 
control design with multiple clinicians is 
necessary for a more rigorous evaluation 
of MAAT efficacy. 
A related concern with MAAT research 
to date is power-either due to small 
sample sizes or the treatment “dosing.” 
Because of this, we modified MAAT to an 
8-visit format as described above. While 
expanding MAAT to 8 visits may add to 
cancer survivor burden (office visits, travel, 
etc.), MAAT still remains a brief CBT and 
retains its practical focus on quality of life 
improvement. We believe this modification 
is justified given results of preliminary 
research and makes good use of available 
data for treatment development. However, 
future research should continue to examine 
the efficacy of the 8-visit format of MAAT 
in larger samples.
Most notably, a final area of concern 
with MAAT research to date is identifying 
outcome measures that most accurately 
assess the clinical targets of MAAT. As 
stated above, neuropsychological testing 
scores can be considered secondary to 
quality of life and functional effects. 
Furthermore, neuropsychological tests may 
not be sensitive to many of the cognitive 
problems cancer survivors experience. The 
key is to identify patient reported outcome 
(PRO) measures that can reflect quality of 
life improvement when cognitive problems 
are hypothetically better managed. In 
previous MAAT studies, the quality of life 
measure used (i.e., the QOL-CS) has only 
one item on cognitive function. It is a 
broad measure of quality of life and does 
not directly assess the impact of cancer 
treatments on quality of life. Further, 
the other self-report measure used in 
previous studies, the MASQ, only assesses 
perceived cognitive symptoms, not quality 
of life impact of cognitive dysfunction. 
The MASQ also does not assess emotional 
impact of cognitive failures of daily life, 
such as anxiety about memory problems. 
In light of these findings, we propose 
using different PRO measures that reflect 
quality of life impact. For example, the 
Functional Assessment of Cancer Therapy-
Cognitive scale (FACT-Cog(57-59)) is a PRO 
measure that may be better suited for 
MAAT outcome research. The FACT-Cog 
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measures subjective cognitive complaints, 
cognitive abilities, comments on cognitive 
function from others and the impact of 
cognitive problems on quality of life(22-60). 
We are primarily interested in the Impact 
on Quality of Life subscale in the current 
research as a primary depended variable. 
At the time of early MAAT development 
and the studies cited above, the FACT-
Cog was not available. However, it is now 
ready for research use and we strongly 
encourage other investigators to use this 
measure. 
The other outcome measure we believe 
to better reflect MAAT’s treatment effects, 
the MIA-Anxiety scale, is a measure of 
anxiety about cognitive function and 
symptoms. This 14-item scale evaluates 
anxiety about perceived memory function 
(e.g., “I get anxious when I am asked to 
remember something”) and thus provides 
an appropriate assessment of emotional 
coping with cognitive failures –a domain 
MAAT is designed to address–. In 
conclusion, it is believed these measures are 
better suited to the clinical targets of MAAT. 
There are also a number of other measures 
that evaluate quality of life or functional 
impact of cognitive problems, in addition 
to perceived cognitive symptoms in daily 
life. For example, the Work Limitations 
Questionnaire (WLQ) evaluates the impact 
that cognitive or other symptoms can have 
on work output(61,62) and has been used to 
assess the impact of cognitive problems on 
work among breast cancer survivors(63). We 
have summarized these and other measures 
in Table 1 and encourage investigators to 
consider use of these measures in research 
on the cognitive effects of chemotherapy 
among cancer survivors.
OTHER TREATMENTS
Aside from MAAT, there are other 
behavioral and computer-based inter ven-
tions that are being developed and studied 
among cancer survivors with cognitive 
complaints. One intervention, the 
Cognitive-Behavioral Model of Everyday 
Memory (CBMEM)(64) is a group intervention 
that consists of eight, 90-minute visits with 
four weekly, 2-hour follow-up or “booster 
visits.” The intervention was principally 
designed for older adults but there is 
one published study with a small cancer 
survivorship sample consisting of 8 cancer 
survivors in the active treatment and 14 
randomized to a health information/
education control condition. Results of this 
study suggest that CBMEM survivors tended 
to score better in memory self-efficacy and 
locus of control with regard to handling 
memory problems. CBMEM, similar to 
MAAT, consists of several components and 
emphasizes mastery of strategy training 
to promote self-efficacy in use of and 
application of memory strategies in daily 
life. While more rigorous study of CBMEM 
is necessary, the target of CBMEM on self-
efficacy and mastery of self-management of 
daily cognitive performance is intriguing.
A computerized treatment program is 
currently being investigated as a treatment 
of chemotherapy-related cognitive 
dysfunction(65). The intervention, the Brain 
Fitness Program by Posit Science of San 
Francisco, CA, utilizes a series of repetitive 
computer-based auditory processing 
speed exercises that provides performance 
feedback to the user. Continual adjustment 
by the computer to the user’s performance 
is made to so the user is performing at 
about 85% success continuously. Training 
is based on forty 1-hour sessions (5 days per 
week of 1-hour sessions over 8 weeks). One 
RCT of older adults did produce moderate 
positive effects in neuropsychological 
test scores verbal-auditory immediate 
and delayed recall domains among those 
treated versus participants randomized to 
an educational control condition(66). The 
authors interpreted results that the speed 
of processing improvements generalized 
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across neuropsychological domains. 
However, the neuropsychological test 
results were on tests that are presented in 
auditory fashion, so it remains in debate 
whether improved speed of processing 
will significantly affect daily behavioral 
performance in functional tasks or 
positively affect daily quality of life. 
Nevertheless, this computer-based method 
may hold promise for cancer survivors and 
investigations remain ongoing. 
A final example of another intervention 
that has potential of helping cancer survivors 
with cognitive problems after cancer 
treatment is “C-Car and Strategy Training” 
by Gehring and colleagues(67). This cognitive 
rehabilitation program actually combines 
a computerized training program with a 
compensatory strategy approach. C-Car 
was designed to treat individuals with 
moderate cognitive dysfunction secondary 
to gliomas. The overall program consists 
of 6 weekly, 2-hour training sessions. 
The computer-based component involves 
a computer display view of simulated 
automobile driving and an oncoming 
roadway. Hierarchically graded “driving” 
tasks that demand greater and faster 
attention are presented, and performance 
feedback is provided. Glioma survivors 
are also trained in psychoeducation 
sessions in compensatory strategy training. 
In a randomized, wait-list control trial, 
participants in C-Car improved in attention 
and verbal memory at 6 month follow-up. In 
addition, improvements were seen treated 
individuals in self-reported cognitive 
failures at post-treatment and 6-month 
follow-up that was significantly different 
from controls. It is not known if C-Car can 
help reduce anxiety about cognitive failures 
or reduce negative quality of life impact of 
cognitive symptoms among those treated. 
Further, C-Car has not been evaluated 
yet in an active control condition among 
individuals with cognitive dysfunction 
secondary to chemotherapy or other 
cancer treatment, and who do not have 
CNS disease. Nevertheless, the high quality 
of the waitlist RCT and the combination of 
computer-based processing speed training 
with compensatory strategies holds great 
promise for C-Car as an intervention for 
cancer survivors with chemotherapy-
related cognitive problems. 
PHARMACOTHERAPY 
In addition to the behavioral and 
computer-based interventions described 
above, drug interventions for chemotherapy-
related cognitive dysfunction have also 
been investigated. For example, an 
8-week double-blind placebo control trial 
of dexmethylphenidate (d-MPH; Focalin; 
mean of 27.7mg/day) was conducted with 
152 adult patients with various cancers 
(excluding patients with primary or 
metastatic CNS tumors) (68). Improvements 
in fatigue and the memory score of the 
Highly Sensitive Cognitive Screen (HSCS) 
were observed among active medication 
participants vs. placebo. In another study, 
a sample of 68 breast cancer survivors 
with chemotherapy-cognitive complaints 
(mean of 22.8 months after last treatment) 
completed a trial of modafinil vs. placebo(69). 
Participants were assessed with the Cognitive 
Drug Research (CDR) computerized 
neuropsychological assessment and the 
Brief Symptom Inventory at baseline and 
after 4 weeks. Significant improvements in 
the Speed of Memory Index (p = .0002) 
and Digit Vigilance sub-tests of the CDR 
were observed in the participants taking 
modafinil while no significant gains in 
the placebo group were observed. Taken 
together, these results suggest that there 
may be some clinical benefit for such 
medications, although more research is 
needed. Furthermore, cancer survivors 
may prefer effective non-drug alternatives 
after primary cancer treatment to either 
reduce the number of medications taken 
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or minimize side effects(7,70). For instance, 
in the d-MPH trial cited above, 40.8% 
of participants reported mild/moderate 
headache, in addition to 27.6% reporting 
nausea. In light of our poor understanding 
of the etiology of cognitive effects of 
chemotherapy and potential for medication 
side effects and interactions, continued 
development of non-pharmacological 
approaches to cognitive dysfunction 
can offer survivors lower risk treatment 
alternatives. 
DISCUSSION
Much research on the causality and 
treatment of cognitive effects of cancer 
chemotherapies remains to be done. 
Despite growing recognition of cognitive 
disturbance following chemotherapy 
among cancer survivors, research on 
effective treatments is still developing. 
This article has summarized some of 
the empirical support to date regarding 
MAAT as one of the emerging treatment 
approaches and high-lighted limitations 
in the research to date. In addition, we 
outlined the importance of identifying 
patient reported outcome measures that 
may be better suited for evaluating the 
quality of life and functional impact 
of late cognitive effects of cancer 
treatment— the clinical targets that MAAT 
is designed to affect, perhaps more so 
than neuropsychological test performance. 
Regardless of current knowledge of the 
etiology of chemotherapy-related cognitive 
problems, continued development and 
refinement MAAT or similar treatments is 
strongly encouraged especially in light of 
the large and growing numbers of cancer 
survivors.
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